Literature DB >> 16227351

COX-2 chronology.

C J Hawkey1.   

Abstract

The role of selective cyclooxygenase (COX)-2 inhibitors in medical practice has become controversial since evidence emerged that their use is associated with an increased risk of myocardial infarction. Selective COX-2 inhibitors were seen as successor to non-selective non-steroidal anti-inflammatory drugs, in turn successors to aspirin. The importance of pain relief means that such drugs have always attracted attention. The fact that they work through inhibition of cyclooxygenase, are widespread, and have multiple effects also means that adverse effects that were unanticipated (even though predictable) have always emerged. In this paper I therefore present an historical perspective so that the lessons of the past may be applied to the present.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227351      PMCID: PMC1774747          DOI: 10.1136/gut.2005.065003

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  47 in total

1.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Authors:  Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

2.  Aspirin in the treatment of vascular diseases.

Authors:  P C GIBSON
Journal:  Lancet       Date:  1949-12-24       Impact factor: 79.321

3.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Authors:  Nancy A Nussmeier; Andrew A Whelton; Mark T Brown; Richard M Langford; Andreas Hoeft; Joel L Parlow; Steven W Boyce; Kenneth M Verburg
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

4.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

5.  Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.

Authors:  Michael Hayden; Michael Pignone; Christopher Phillips; Cynthia Mulrow
Journal:  Ann Intern Med       Date:  2002-01-15       Impact factor: 25.391

6.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

7.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue.

Authors:  D A Kujubu; B S Fletcher; B C Varnum; R W Lim; H R Herschman
Journal:  J Biol Chem       Date:  1991-07-15       Impact factor: 5.157

8.  A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.

Authors:  N D Yeomans; Z Tulassay; L Juhász; I Rácz; J M Howard; C J van Rensburg; A J Swannell; C J Hawkey
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

9.  Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

Authors:  C J Hawkey; J A Karrasch; L Szczepañski; D G Walker; A Barkun; A J Swannell; N D Yeomans
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

Review 10.  From plant extract to molecular panacea: a commentary on Stone (1763) 'An account of the success of the bark of the willow in the cure of the agues'.

Authors:  John N Wood
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-04-19       Impact factor: 6.237

View more
  9 in total

Review 1.  The discovery of aspirin's antithrombotic effects.

Authors:  Jonathan Miner; Adam Hoffhines
Journal:  Tex Heart Inst J       Date:  2007

2.  Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin.

Authors:  Harald Vonkeman; Inger Meek; Mart van de Laar
Journal:  Drug Healthc Patient Saf       Date:  2010-10-06

Review 3.  Development of Antioxidant COX-2 Inhibitors as Radioprotective Agents for Radiation Therapy-A Hypothesis-Driven Review.

Authors:  Markus Laube; Torsten Kniess; Jens Pietzsch
Journal:  Antioxidants (Basel)       Date:  2016-04-19

Review 4.  Evidence and consensus recommendations for the pharmacological management of pain in India.

Authors:  Gur Prasad Dureja; Rajagopalan N Iyer; Gautam Das; Jaishid Ahdal; Prashant Narang
Journal:  J Pain Res       Date:  2017-03-29       Impact factor: 3.133

Review 5.  Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders.

Authors:  Rickinder Sethi; Nieves Gómez-Coronado; Adam J Walker; Oliver D'Arcy Robertson; Bruno Agustini; Michael Berk; Seetal Dodd
Journal:  Front Psychiatry       Date:  2019-09-04       Impact factor: 4.157

6.  Deuteration versus ethylation - strategies to improve the metabolic fate of an 18F-labeled celecoxib derivative.

Authors:  Markus Laube; Cemena Gassner; Christin Neuber; Robert Wodtke; Martin Ullrich; Cathleen Haase-Kohn; Reik Löser; Martin Köckerling; Klaus Kopka; Torsten Kniess; Evamarie Hey-Hawkins; Jens Pietzsch
Journal:  RSC Adv       Date:  2020-10-20       Impact factor: 4.036

Review 7.  Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing.

Authors:  Afaf A El-Malah; Magdy M Gineinah; Pran Kishore Deb; Ahdab N Khayyat; Monika Bansal; Katharigatta N Venugopala; Anfal S Aljahdali
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-03

Review 8.  Different Chemical Structures and Physiological/Pathological Roles of Cyclooxygenases.

Authors:  Yalcin Faki; Ayse Er
Journal:  Rambam Maimonides Med J       Date:  2021-01-19

Review 9.  From NSAIDs to Glucocorticoids and Beyond.

Authors:  Ajantha Sinniah; Samia Yazid; Rod J Flower
Journal:  Cells       Date:  2021-12-14       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.